A Study to Evaluate the Safety, Tolerability and Efficacy of MHV370 in Participants With Sjogren's Syndrome (SjS) or Mixed Connective Tissue Disease (MCTD)

Phase 2 Terminated 30 enrolled Novartis Pharmaceuticals

RandomizedParallel-groupTriple-blindTreatment

Summary

This study was a basket trial designed to establish safety, tolerability and efficacy of MHV370 in Sjögren's Syndrome (SjS) and Mixed Connective Tissue Disease (MCTD).

Timeline

Start: 2021-11-30
Primary completion: 2023-02-07
Completion: 2023-03-07

Outcome

Outcome not reported

Stopped (Business): “Sponsor decision”

Publications

Raaphorst J, Gullick NJ, Shokraneh F, Brassington R, Min M, Ali SS, Gordon PA. Non-targeted immunosuppressive and immunomodulatory therapies for idiopathic inflammatory myopathies. Cochrane Database Syst Rev. 2025 Aug 11;8(8):CD015855. doi: 10.1002/14651858.CD015855.
Raaphorst J, Gullick NJ, Shokraneh F, Brassington R, Min M, Ali SS, Gordon PA. Targeted immunosuppressive and immunomodulatory therapies for idiopathic inflammatory myopathies. Cochrane Database Syst Rev. 2025 Aug 1;8(8):CD015854. doi: 10.1002/14651858.CD015854.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MHV370	Small molecule	—	—